CaMKII Inhibition is a Novel Therapeutic Strategy to Prevent Diabetic Cardiomyopathy

Increasing prevalence of diabetes mellitus worldwide has pushed the complex disease state to the foreground of biomedical research, especially concerning its multifaceted impacts on the cardiovascular system. Current therapies for diabetic cardiomyopathy have had a positive impact, but with diabetic...

Ամբողջական նկարագրություն

Պահպանված է:
Մատենագիտական մանրամասներ
Հիմնական հեղինակներ: Christopher R. Veitch (Հեղինակ), Amelia S. Power (Հեղինակ), Jeffrey R. Erickson (Հեղինակ)
Ձևաչափ: Գիրք
Հրապարակվել է: Frontiers Media S.A., 2021-07-01T00:00:00Z.
Խորագրեր:
Առցանց հասանելիություն:Connect to this object online.
Ցուցիչներ: Ավելացրեք ցուցիչ
Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_488cd6ad52b846b9a79a72da0c5ff58d
042 |a dc 
100 1 0 |a Christopher R. Veitch  |e author 
700 1 0 |a Amelia S. Power  |e author 
700 1 0 |a Jeffrey R. Erickson  |e author 
245 0 0 |a CaMKII Inhibition is a Novel Therapeutic Strategy to Prevent Diabetic Cardiomyopathy 
260 |b Frontiers Media S.A.,   |c 2021-07-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2021.695401 
520 |a Increasing prevalence of diabetes mellitus worldwide has pushed the complex disease state to the foreground of biomedical research, especially concerning its multifaceted impacts on the cardiovascular system. Current therapies for diabetic cardiomyopathy have had a positive impact, but with diabetic patients still suffering from a significantly greater burden of cardiac pathology compared to the general population, the need for novel therapeutic approaches is great. A new therapeutic target, calcium/calmodulin-dependent kinase II (CaMKII), has emerged as a potential treatment option for preventing cardiac dysfunction in the setting of diabetes. Within the last 10 years, new evidence has emerged describing the pathophysiological consequences of CaMKII activation in the diabetic heart, the mechanisms that underlie persistent CaMKII activation, and the protective effects of CaMKII inhibition to prevent diabetic cardiomyopathy. This review will examine recent evidence tying cardiac dysfunction in diabetes to CaMKII activation. It will then discuss the current understanding of the mechanisms by which CaMKII activity is enhanced during diabetes. Finally, it will examine the benefits of CaMKII inhibition to treat diabetic cardiomyopathy, including contractile dysfunction, heart failure with preserved ejection fraction, and arrhythmogenesis. We intend this review to serve as a critical examination of CaMKII inhibition as a therapeutic strategy, including potential drawbacks of this approach. 
546 |a EN 
690 |a CaMKII 
690 |a diabetes 
690 |a O-GlcNAc 
690 |a oxidation 
690 |a nitrosylation 
690 |a arrhythmia 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 12 (2021) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2021.695401/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/488cd6ad52b846b9a79a72da0c5ff58d  |z Connect to this object online.